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Amyloid deposition occurs in healthy aging even in individuals free from cognitive 
symptoms. In addition, newer CSF markers, such as YKL-40, can track 
neuropathological brain processes such as inflammation. Altered YKL-40 levels are 
described in Alzheimer’s disease (AD), but little is known about their correlations 
with brain and cognition in healthy older adults. From a longitudinal sample, we 
selected 89 participants having CSF samples at baseline, and both MRI and cognitive 
assessments from two time-points separated by two years. Mean age at inclusion was 
73.1 years (SD: 6.01). We tested how baseline CSF levels of Aβ42 and YKL-40 
predicted changes in cortical thickness and in cognition. We found correlations 
between longitudinal cortical thinning and Aβ42 only in amyloid positive participants 
(< 600 pg/mL, n=27). Aβ42 did not predict change in cognitive scores, while 
increased YKL-40 was associated with less memory preservation in the total sample 
(r=-0.28, p=0.012) and less preservation of global cognition for amyloid positive 
participants (r=-.58, p=0.004). Our results suggest a role of inflammation in brain 
structure and cognitive changes in healthy aging, which may be partly dependent on 
amyloid status.  
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Low level of cerebrospinal fluid (CSF) Aβ42 represents a major risk factor for 
Alzheimer’s disease (AD) (Blennow et al., 2010) but is also a commonly described 
feature within clinically normal aging populations (Mormino, 2014). We still do not 
understand why Aβ is related to the development of disease in some persons, while 
others seem able to cope with substantial amyloid burden. Therefore, many studies 
point to an inconsistent relationship between Aβ, brain atrophy and cognition in 
aging, which can be caused by other factors that interact with amyloid (Chételat et al., 
2016). In this sense, neuroinflammation has been proposed as one critical factor. 
Similar to amyloid, neuroinflammation occurs in both AD and normal aging 
(Fleischman et al., 2010; Heneka et al., 2015). Although neuroinflammation is 
observed in pathologically vulnerable brain regions in AD, it remains unclear whether 
insoluble Aβ deposits or neurofibrillary tangles are causing inflammation (Akiyama et 
al., 2000) or whether inflammation may actually promote or accelerate deposition of 
Aβ (Lee et al., 2008). In addition, by means of neuropathological studies, we know 
that increasing age is associated with increased microglial activation accompanied by 
production of inflammatory cytokines and compromised neuronal function, including 
synaptic dysfunction (Costello et al., 2016). The chitinase-3-like protein 1 (YKL-40) 
is a CSF biomarker reflecting neuroinflammation (Craig-Schapiro et al., 2010). Some 
studies have reported increased YKL-40 in AD (Rosén et al., 2014), predicting 
conversion to dementia (Antonell et al., 2014; Craig-Schapiro et al., 2010; Janelidze 
et al., 2016). YKL-40 has also been related to brain atrophy in AD (Alcolea et al., 
2015; Gispert et al., 2016). However, the capabilities of YKL-40 to distinguish AD 
from controls have so far been found to be moderate in comparison with other CSF-
markers such as T-tau, P-tau and Aβ42 (Olsson et al., 2016), and some report no 
relationship with AD (Hellwig et al., 2015; Mattsson et al., 2011). This may suggest 
that YKL-40 levels correlate with brain and cognitive processes just as much in 
normal aging as in AD.  
 
In the present study, we tested the role of neuroinflammation in cortical atrophy and 
cognitive reductions in older adults without cognitive symptoms with either abnormal 
or normal amyloid status. Baseline measures of Aβ42 and YKL-40 were used to 
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predict cortical thinning and change in cognitive test scores over time. Although there 
are reasons to expect a relationship between amyloid levels and neuroinflammation, 
no previous study has directly tested how these biomarkers interact in predicting brain 
and cognitive decline in aging. While the role of YKL-40 in normal aging is almost 
unexplored, previous research on amyloid-related changes in the aging brain are 
conflicting, with some reporting more atrophy (Fagan et al., 2009; Schott et al., 2010; 
Tosun et al., 2010) in subjects with lower CSF Aβ42 levels and others larger volumes 
(Chételat et al., 2010), or non-linear relationships (Fortea et al., 2011). It has also 
been suggested that the correlations between Aβ42 and atrophy can be different for 
Aβ positive vs. negative individuals. This has been described in the Alzheimer’s 
Disease Neuroimaging Initiative (ADNI) database (Becker et al., 2011; Fjell et al., 
2010), but has not to our knowledge been tested in other independent samples. With 
regard to cognitive changes, studies indicate that amyloid levels correlate, albeit not 
strongly, with cognitive function in normal populations (Hedden et al., 2013). 
Because of these controversies, it is necessary to study other factors that may show 






The sample consisted of cognitively healthy older adults. Exclusion criteria were 
dementia, previous stroke with sequelae, Parkinson’s disease or other neurological 
condition likely to affect cognition (see details in Idland et al., in press). From the full 
sample recruited, which included 172 participants, we selected those having available 
baseline CSF measures and both MRI and cognitive evaluation at the two timepoints 
(mean time between MRI scans: 2.18 years). A total of 89 participants were included 
in the current analyses. Demographics are summarized in Table I. The cognitive 
evaluation was identical at the two timepoints and included a range of tests from 
which we selected for the present analyses the Word List Memory Task from the 
Consortium to Establish a Registry for Alzheimer’s Disease battery (CERAD)(ref) the 
Animal Naming Test (ANT)(ref) and the Trail Making Test B (TMTB) (ref), to 
represent different cognitive domains. 
 
2.2. Rates of change and cognition factor 
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We computed the annual rate of change in the scores obtained from the cognitive tests 
using the symmetrized annual percent change. These values were obtained as the 
difference of the scores between timepoints divided by its mean and by the time 
between them. The obtained scores are referred to as: CERAD-change, ANT-change, 
and TMTB-change.  
We also calculated a global cognition change factor using Principal Component 
Analysis (PCA) on the rates of change obtained from the three tests. We refer to this 
score as COGfac-change.     
 
2.3. CSF measures 
CSF samples were taken at the time of the induction of spinal anesthesia. CSF was 
collected in polypropylene tubes, centrifuged, the supernatant aliquoted in 
polypropylene vials, frozen as soon as possible, and stored at -80°C. CSF was thawed, 
aliquoted once more in polypropylene vials and frozen again before it was sent for 
analyses. Levels of Aβ42 were determined using INNOTEST enzyme-linked 
immunosorbent assays (Fujirebio, Ghent, Belgium). YKL-40 concentrations were 
measured using a commercially available ELISA (R&D systems, Minneapolis, MN). 
All analyses were performed by board-certified laboratory technicians, who were 
masked to clinical data, using one batch of reagents with intra-assay coefficients of 
variation below 10 %.  
 
2.2. Magnetic Resonance Imaging 
In each scanning session, a T1-weighted MPRAGE 3D image was acquired in a 1.5T 
Siemens Avanto scanner using a 12-channel head coil (TR=2400 ms, TE=3.79ms, 
slice thickness=1.20mm, pixel spacing=1.25x1.25mm).  
 
2.3. MRI processing 
Structural MPRAGE scans were processed with FreeSurfer (version 5.3) and its 
longitudinal stream (https://surfer.nmr.mgh.harvard.edu). The standard FreeSurfer 
pipeline performs a set of automated procedures for the cortical reconstruction and 
volumetric segmentation of the individual scans (Dale et al., 1999; Fischl et al., 
2002). In addition, the FreeSurfer longitudinal stream includes a set of methods 
designed to minimize the bias to any time point and which has been shown to lead to 
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increased statistical power, better separation of groups based on atrophy and higher 
reproducibility (Jovicich et al., 2013; Reuter and Fischl, 2011; Reuter et al., 2012). 
Using these tools, we obtained vertex-wise maps of symmetrized atrophy rate, defined 
as the normalized difference in thickness at each vertex per year. 
FreeSurfer reconstructed brain surfaces were visually inspected and manually 
corrected when necessary. Manual interventions included the removal of non-brain 
areas and the use of control points to guide the automated reconstruction of white and 
pial surfaces.  
 
2.4. Statistics.  
The surface-based data representing thickness change for each subject was fit into a 
GLM model for group-statistics. We first calculated the mean rate of change between 
acquisitions for the whole sample (i.e., one-sample t-test). We then performed vertex-
wise correlations and tested interactions to investigate relationships between 
thickness, CSF markers and cognition. Age and gender were introduced as covariates 
in all the surface-based analyses. Maps were corrected for family wise-error (FWE) 
using precomputed simulated data in FreeSurfer (Hagler et al., 2006). Significance 
threshold was set at a p-value of 0.05, both for the initial thresholding of the maps and 
for the identification of significant clusters.   
In addition, we repeated the longitudinal analysis using a Linear Mixed Effects 
(LME) analysis implemented in Matlab and distributed as part of the FreeSurfer 
Pipeline (Supplementary Material). 
Statistics on non-imaging data were performed with SPSS and MATLAB tools. These 




3. 1. Demographics and cognitive data 
Participants were divided into two subgroups according to their levels of CSF Aβ42, 
Aβ+ (< 600 pg/mL) and Aβ- (≥ 600 pg/mL). Because several cutoff values of CSF 
Aβ42 levels are described in the literature, ranging from 500 to 650 pg/mL (Fagan et 
al., 2009; Mulder et al., 2010; Niemantsverdriet et al., 2016; Zwan et al., 2016), we 
used a rather conservative level of 600 pg/mL to accommodate possible variation or 
bias in the measurements and to ensure a considerable number of subjects within the 
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group of healthy older adults with amyloid positivity. A total of 27 subjects were 
included in the Aβ+ group and 62 in the Aβ- group. There were no group differences 
in the rates of change in any of the cognitive measures or in baseline CSF YKL-40 
and Tau levels. The results of the TMTB at the second timepoint differed between 
groups (t=2.54, p=0.016), however, the rates of change within this measure were 
comparable (t=1.3, p=0.16).  
 
 Full sample 
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Sex  (men/women) 46/43 29/33 17/10 
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CSF biomarkers    






CSF – T-Tau (pg/ml) 373.4 (142.05) 
114.7-785.9 
361.28 (123.27) 
181.8 – 767.9 
401.23 (177.45) 
114.7-785.95 






YKL-40 (ng/ml) * 220.02 (73.9)*103 
92.11 - 441.5*103  
219.80 (73.39) *103 
97.19 – 441.5 *103  
220.521 (76.47) *103 
92.11-348.3 *103 
 
Table I: Sample summary. Demographics, cognititive and CSF data of all participants included in the 
analyses.  
+ Missing cognitive data of N=1 subject 
* excluded 1 subject below detection limit 
 
3.3. Mean longitudinal changes in cortical thickness 
We observed an average rate of cortical thinning of 0.53% (SD: 1%) per year in the 
full sample. General thinning was observable across large regions of the cortex 
(Figure 1).  Reductions in cortical thickness were significant (FWE corrected level of 
p<0.05) in several clusters located bilaterally in superior parietal, supramarginal, 
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precuneus, isthmus cingulate posterior cingulate, postcentral and paracentral cortices, 
in the right hemisphere including the superior frontal, caudalmiddlefrontal, inferior 






Figure 1. Mean effects of time on cortical thickness within the full sample. Percentage of thickness 
change measured between baseline and the 2-years scan. Green-blue areas indicate decreases over time 
and yellow-red indicate increases (see legend).  
 
3.4. Aβ42 and cortical thinning 
Overall change in cortical thickness did not differ between Aβ+ and Aβ- participants 
(-0.50% and -0.54 % respectively, t=0.11, p=0.91). We used a vertex-wise GLM on 
the surface to investigate the effect of CSF Aβ42 levels on regional thickness change. 
Using a between-group comparison, we found that regional change in thickness did 
not differ between groups. We then created a design with separate slopes for the Aβ+ 
and the Aβ- groups and tested it across the whole cortex. We found a cluster where 
this interaction was significant, located in the xxx (p<0.05, FWE corrected). In this 
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region there was a negative relationship between CSF Aβ42 levels and the reduction 




Figure 2. (A) Region with a group-interaction with Aβ42 levels and cortical thickness change. (B) 
Scatter plots showing the relationship between thickness change and Aβ42 levels for the two groups 
separately. 
 
3.5. Aβ42 and cognition 
We did not find any relationship between CSF levels of Aβ42 and the global 
cognitive change or change in any of the specific cognitive measures.  
 
3.6. YKL and cortical thinning 
We did not find any relationship between change in cortical thickness and YKL-40. 
We tested for direct relationships as well as for interactions with CSF Aβ42 levels.  
 
3.5. YKL and cognition 
Change in the animal naming test (ANT-change) correlated with CSF YKL-40 levels 
within the whole sample, in that higher YKL-40 levels were related to more negative 
change (r=-0.28, p=0.012) (Figure 3A). Note that we observed rates of change above 
zero due to practice effects (Galvin et al., 2005). No significant correlations between 
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YKL-40 and the other cognitive measures were found, but a trend was observed 
between YKL-40 and global cognition change (r=-0.185, p=0.096). 
Finally, we explored correlations with the CSF YKL-40 levels and cognition in Aβ+ 
and Aβ- participants. In the Aβ+ group, we found a correlation between levels of 
YKL40 and the cognition change factor (r=-.58, p=0.004, see Figure 3B), indicating 
less cognitive maintenance. This correlation was not found in the Aβ- group (r=-
0.008, p=0.955). These correlations were significantly different, as evidenced by use 
of the Fisher r-to-z transformation (z = 2.72, p = .0065, two-tailed).  
 
 
Figure 3. CSF YKL levels and cognition. (A) YKL-40 and changes in animal naming test in the full 
sample. (B) Correlation between YKL and global cognition in Aβ+ and Aβ- participants. 
 
 
3.6. Cortical Thickness and cognition 
Longitudinal change in cortical thickness correlated positively with change in the 
results of the animal naming test (p<0.05), meaning that more thinning was associated 
with reduction or less maintenance of cognitive scores. We found two significant 
clusters located in the right hemisphere, covering parts of the supramarginal, 
postcentral, and inferior parietal cortices (Figure 4).  
 
 
Figure 4. Correlation between change in cortical thickness and change in the results of the animal 
naming test. Red-yellow areas indicate that changes in thickness and changes in cognition have the 





In the present study we showed that neuroinflammation, as indexed by CSF levels of 
YKL-40, predicted reduced cognitive function two years later in cognitively normal 
older adults who were positive for Aβ. Intriguingly, no relationship was observed for 
Aβ negative participants. As CSF levels of Aβ42 and YKL40 were not related, this 
could indicate that these biomarkers are indicators of distinct processes in the brain 
that have additive detrimental effects on cognitive function in older adults at risk for 
AD. In addition, we found that CSF Aβ42 levels predicted cortical atrophy only in 
amyloid positive participants. Seen together, these results indicate that mechanisms 
for brain atrophy and cognitive decline might be different in older adults that are 
positive in comparison with those negative for amyloid, underscoring the need to 
understand how amyloid relates to brain atrophy in cognitively normal older adults. 
The implications of the results are discussed below. 
 
Neuroinflammation and cortical thinning in Aβ positive older adults 
Here we used CSF YKL-40 levels as a measure of neuroinflammation and we found 
that increased levels of this biomarker predicted global changes in cognition in the 
Aβ+ group, indicating that neuroinflammation might play an important role for 
cognitive changes in older adults with altered amyloid status. In addition, increasing 
age has been associated with increased microglial activation (Costello et al., 2016). 
Abnormal, increased levels of CSF YKL-40 are observed in AD patients (Craig-
Schapiro et al., 2010; Janelidze et al., 2016; Olsson et al., 2016), but this is not 
invariably found (Hellwig et al., 2015; Mattsson et al., 2011). However, no studies 
have previously tested whether this biomarker is increased also in healthy older adults 
with altered amyloid levels. Intriguingly, our result suggests that even if the level of 
neuroinflammation as indexed by YKL-40 does not vary as a function of amyloid 
accumulation, the ability of the brain to cope with the inflammation is different 
depending on the subject amyloid status. Thus, inflammation predicts cognitive 
reduction over time in the presence of higher amyloid levels only, with the lower risk 
older adults probably being able to better cope with the burden of neuroinflammation. 
This is not an on-off mechanism, however, as we found that changes in verbal 
memory correlated with YKL-40 levels also within the full sample. Thus, the present 
results indicate that YKL-40 indexes neuroinflammatory processes that have mild but 
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nevertheless detrimental effects on cognitive function in older adults, and that these 
detrimental effects are significantly larger in participants with increased Aβ42 levels.  
 
Cortical thinning at the different CSF Aβ42 levels 
In addition to the Aβ-dependent effects of neuroinflammation on cognition, we found 
that decreased CSF Aβ42 correlated with cortical thinning in the Aβ+ participants. 
This further indicate that there might be degenerative processes occurring at this 
narrow range of Aβ42 levels even in individuals free from clinical symptoms. This 
pattern has previously been described within the ADNI cohort of normal older adults 
(Becker et al., 2011; Fjell et al., 2010). These two studies found that only under a 
certain threshold of Aβ42 levels in CSF, Aβ42 correlated with accelerated brain 
atrophy. The present study demonstrates this pattern in a different sample than the 
ADNI database. Taken together, these findings indicate that amyloid positive older 
adults are less able to cope with processes in the brain that might otherwise not be as 
harmful in older adults without evidence of brain amyloid accumulation.   
 
Neuroinflammation, amyloid and changes in cognition 
Previous literature has described null or relatively weak relationships between 
common CSF AD biomarkers such as Aβ42 and memory/cognition in healthy elderly 
participants (Aschenbrenner et al., 2015; Fjell et al., 2014; Hedden et al., 2013). This 
has encouraged the community to study the roles of alternative markers in addition to 
amyloid to better explain cognitive reductions and brain atrophy in aging. Our results, 
though being moderate in strength, indicate that YKL-40 is one such marker, 
primarily when seen in coexistence with altered levels of established risk markers 
such as Aβ42. This fits with theories of amyloid and neuroinflammation working 
together to cause decline in older adults with neurodegenerative conditions such as 
AD (Heneka et al., 2015), even if the evidence for these theories in humans is scarce 
and to a large extent based on genetic studies. Further, additive roles of amyloid 
accumulation and neuroinflammation have not been tested in cognitively normal older 
adults. The results of the present study suggest that effects of inflammation on 
cognitive decline in non-demented may partly depend on amyloid status. Adding to 
this, we found that the same cognitive test also correlated with longitudinal changes in 
cortical thickness. Participants with less capability to maintain or improve 
performance on the animal naming test showed more decreases in cortical thickness. 
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These results are in accordance with previous studies showing correlations between 
longitudinal changes in brain structure and changes in cognition (Fjell et al., 2013; 
Persson et al., 2016; Rodrigue and Raz, 2004).  
Although being predictive of cognitive reductions, CSF YKL-40 levels did not 
correlate with cortical thinning. Some previous studies have reported correlations 
between thinner cortex and higher YKL-40 levels (Alcolea et al., 2015; Gispert et al., 
2016) or other markers of inflammation (Fleischman et al., 2010), while others did 
not find relationships with measures of brain structures such as hippocampal volume 
(Melah et al., 2015). The studies mentioned above were all cross-sectional, in contrast 
to the present longitudinal design. Further, these former studies included patients with 
MCI or AD, thus not being fully comparable. Still, when the present results are seen 
in contrast to the identified relationship between amyloid levels and cortical thinning 
in the amyloid positive participants, it is evident that the relationship between amyloid 
levels, neuroinflammation and brain atrophy is complex. To get a deeper 
understanding of the mechanisms at play, we will likely also need to include 
additional biomarkers as well as genetic factors in the analyses.  
 
Conclusion: One important theory holds that sustained inflammatory responses to 
amyloid accumulation increase brain atrophy in AD (Gouwens et al., 2016; Heneka et 
al., 2015), and the increased levels of neuroinflammation observed also in cognitively 
normal older adults make it important to investigate amyloid – inflammation 
relationships also in non-demented. Here we found that YKL-40, as a measure of 
neuroinflammation, correlated with cognitive reductions in amyloid positive older 
adults only. In contrast, CSF Aβ42 levels per se did not predict cognitive decline, but 
still were related to brain atrophy in amyloid positive participants. Put together, these 
findings highlight the need for considering how newer biomarkers interact with the 
established ones in predicting cognitive and brain changes in aging. This may provide 
better understanding of the processes that are crucial in the transitional phase between 
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